Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued [GID-TA10970]
Search results
56 results
-
-
Breast cancer - intensity modulated radiotherapy [ID16]
Discontinued [GID-TAG390]
-
Juvenile idiopathic arthritis - abatacept [ID27]
Discontinued [GID-TAG402]
-
Prostate cancer - intensity modulated radiotherapy [ID17]
Discontinued [GID-TAG396]
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
Discontinued [GID-TAG372]
-
Venous thromboembolism (VTE) - ximelagatran [ID396]
Discontinued [GID-TAG378]
-
Hernia
Discontinued [GID-CGWAVE0771]
-
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
Discontinued [GID-TA10236]
-
Falls - faller's clinics [ID103]
Discontinued [GID-TAG375]
-
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]
Discontinued [GID-TAG398]
-
Diabetic foot ulcers - new treatments [ID381]
Discontinued [GID-TAG371]
-
Venous leg ulcers - new treatments [ID394]
Discontinued [GID-TAG370]
-
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued [GID-TAG411]
-
LJ TEST
Discontinued [GID-TA10462]
-
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]
Discontinued [GID-TAG404]
-
Multiple sclerosis - sativex [ID387]
Discontinued [GID-TAG368]
-
Workplace health for employees with disabilities and long-term conditions
Discontinued [GID-PHG58]
-
Kidney transplantation (rejection) - belatacept [ID87]
Discontinued [GID-TAG239]
-
Accident and emergency departments
Discontinued [GID-SGWAVE0762]
-
Workplace health - older employees
Discontinued [GID-PHG59]
-
Diagnostic services
Discontinued [GID-CGWAVE0773]
-
Personal, social, health and economic education focusing on sex and relationships and alcohol education
Discontinued [GID-PHG0]
-
Inpatient mental health settings
Discontinued [GID-SGWAVE0701]
-
Psoriatic arthritis (moderate to severe) - leflunomide [ID391]
Discontinued [GID-TAG385]
-
Juvenile idiopathic arthritis - adalimumab [ID385]
Discontinued [GID-TAG400]
-
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued [GID-TAG416]
-
Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]
Discontinued [GID-TAG408]
-
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
Discontinued [GID-TA10087]
-
Atrial fibrillation - ximelagatran [ID376]
Discontinued [GID-TAG377]
-
Kidney transplantation (rejection) - everolimus [ID117]
Discontinued [GID-TAG241]
-
Mental health community settings
Discontinued [GID-SGWAVE0702]
-
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued [GID-TA10088]
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
Discontinued [GID-TA10502]
-
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
Discontinued [GID-TAG414]
-
Reducing the mortality and morbidity for healthcare associated infections
Discontinued [GID-NG10059]
-
Management and organisational approaches to safe staffing
Discontinued [GID-SGWAVE0761]
-
Leukaemia (acute lymphoblastic) - dasatinib [ID386]
Discontinued [GID-TAG399]
-
Housing: planning to improve health and wellbeing
Discontinued [GID-NG10053]
-
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued [GID-TAG511]
-
Community nursing care settings
Discontinued [GID-SGWAVE0700]
-
Pulmonary arterial hypertension (adults) - drugs [ID12]
Discontinued [GID-TAG382]
-
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued [GID-TAG393]
-
Head and neck cancer - intensity modulated radiotherapy [ID15]
Discontinued [GID-TAG397]
-
Thrombophilia [ID393]
Discontinued [GID-TAG374]
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued [GID-TA10081]
-
Advocacy services for adults with health and social care needs: draft scope consultation
We are listening to your views on this NICE guideline. Comments close 22 January 2021.
-
Advocacy services for adults with health and social care needs: draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 19 July 2022.